New drug SG1827 enters first human tests for Hard-to-Treat cancers
NCT ID NCT06076291
First seen Jul 10, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tumors. The study involves about 122 participants and will test several dose levels to determine the safest and most promising dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SG1827
- What this could lead to
- If safe and effective, SG1827 could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial focused on safety and dosing, so it is unknown whether SG1827 will work against tumors. Side effects are possible and will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Henan Cancer Hospital
Zhenzhou, Henan, 450003, China
-
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, 410013, China
-
The Affiliated Hospital of USTC
Hefei, Anhui, 230001, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110002, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a cancer vaccine train the body to fight advanced tumors?